Investigating how gut bacteria affect immune response in pancreatic cancer.
Mechanistic investigations of microbiome-driven aryl hydrocarbon receptor activity and macrophage function in pancreatic cancer.
This study is looking at how the bacteria in our bodies might affect the immune system and tumor growth in pancreatic cancer, and it aims to find ways to boost the effectiveness of current treatments for patients with this condition.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University Health Network NIH-funded |
| Lab location | 1 site (Toronto, Canada) |
| Project ID | NIH-11066513 on NIH RePORTER |
What this research studies
This research focuses on understanding the role of the microbiome in pancreatic cancer, particularly how it influences immune cell function and the tumor environment. By studying the aryl hydrocarbon receptor (AhR), which is affected by microbial metabolites, the researchers aim to uncover mechanisms that lead to immune suppression in pancreatic ductal adenocarcinoma (PDAC). The team has developed a mouse model to explore these interactions and assess how modifying AhR activity could enhance responses to existing cancer treatments. This could lead to new strategies for improving patient outcomes in pancreatic cancer.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with pancreatic ductal adenocarcinoma who may benefit from novel immunotherapy approaches.
Not a fit: Patients with non-pancreatic cancers or those who are not eligible for immunotherapy may not receive benefits from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment options for pancreatic cancer patients by enhancing the effectiveness of current therapies.
How similar studies have performed: While the specific approach of targeting the microbiome and AhR in pancreatic cancer is relatively novel, there is growing evidence that similar strategies have shown promise in other cancer types.
Where this research is happening
Toronto, Canada
- University Health Network — Toronto, Canada (Active)
Researchers
- Principal investigator: Mcgaha, Tracy L — University Health Network
- Study coordinator: Mcgaha, Tracy L
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.